We have shown previously that intranasal administration of encephalitogenic peptides in
soluble form to H-2u and H-2s mice affords protection from experimental autoimmune
encephalomyelitis (EAE). Here we demonstrate that this method of disease protection can
be induced in C57BL/6 mice by administration of the soluble peptide 35–55 from myelin
oligodendrocyte glycoprotein. This protective effect was demonstrated by the evaluation of
both clinical EAE scores and central nervous system histopathology; the latter showing …